Table 1. Correlations between miR-573 expression and clinicopathological characteristics in prostate cancer patients.

Parameters	N (cases)	miR-573 expression (%)		P value
		Low	High
Age(year)
<55	18	11(61.1)	7(38.9)	0.714
≥55	47	32(68.1)	15(31.9)
Pre PSA(ng / ml)
<4	6	4(66.7)	2(33.3)	0.801
4–10	7	4(57.1)	3(42.9)
>10	52	35(67.3)	17(32.7)
Gleason score
<7	16	6(37.5)	10(62.5)	0.044
7	23	10(43.5)	13(56.5)
>7	26	18(69.2)	8(30.8)
Clinical tumor stage
≤cT2	48	30(62.5)	18(37.5)	0.776
≥cT3	17	13(76.5)	4(23.5)
Ki67
<10%	52	35(67.3)	17(32.7)	0.694
≥10%	13	8(61.5)	5(38.5)
FGFR1
Not overexpressed	43	24(55.8)	19(44.2)	0.029
Overexpressed	22	19(86.4)	3(13.6)
GATA-3
Not expressed	60	42(70.0)	18(30.0)	0.075
Expressed	5	1(20.0)	4(80.0)